HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 417 participants.

Also called NCT01576341

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 417 participants (enrolled count) (from the registry)
Sponsor
Sandoz (from the registry)
Registry
  • NCT NCT01576341
  • EudraCT 2011-002871-40
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Germany, Italy, Poland, Romania, Russia, Türkiye, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01576341. Allocation not applicable; no masking; primary purpose treatment. Start 2012-04 (registry gives no type); primary completion 2014-10 (actual). Results posted on 2017-06-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)
Acronym
SENSE
Intervention (Drug)
HX575 epoetin alfa (Sandoz)
Lead sponsor
Sandoz (class: industry)

Record details

Record id
cardio:ct-nct01576341
Content hash
69a753b901d779020fcfba5b1fb6771ff0e3c30f0f4465edee8871e6def4dbc1